A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Conditions:   Head and Neck Cancer;   Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: Pembrolizumab;   Drug: Placebo
Sponsor:   University of Chicago
Not yet recruiting - verified July 2016

from #ORL via xlomafota13 on Inoreader http://ift.tt/29YNK1F
via IFTTT